Introduction {#S2}
============

*PRPF31* encodes the ubiquitous splicing factor PRPF31, an essential component of the U4/U6.U5 tri-snRNP. The gene is highly conserved throughout evolution, with orthologues in all vertebrate species, invertebrates and lower species, including yeast. Mutations in *PRPF31* have been shown to be a major cause of autosomal dominant retinitis pigmentosa (adRP), accounting for 5% of disease in the UK \[[@R1],[@R2]\].

A unique feature of *PRPF31*-associated adRP is phenotypic non-penetrance, where within affected families there are asymptomatic mutation carriers. This is due to the existence of differentially expressed wildtype *PRPF31* alleles, with co-inheritance of a *PRPF31* mutation and a higher-expressing allele providing protection against clinical manifestation of disease. It has been shown that there is variable expression of *PRPF31* in the general population and, that within mutation carrying families, asymptomatic mutation carriers have more than two-fold higher expression levels of wildtype *PRPF31* compared to symptomatic individuals \[[@R3]--[@R6]\].

One study looked at phenotypic discordance between mutation-carrying siblings and observed that the symptomatic and asymptomatic siblings consistently inherited different wildtype chromosome 19q13 alleles from the non-mutation carrying parent \[[@R7]\]. It is generally thought, therefore, that *cis-*acting factors that affect the level of *PRPF31* expression (such as regulatory region polymorphisms) underlie phenotypic non-penetrance in mutation-carrying families. However, attempts to identify such changes have not yet been successful.

It has also been demonstrated that there is increased expression of both *PRPF31* alleles in asymptomatic mutation-carrying individuals, with subsequent degradation of the mutant molecule by nonsense mediated decay -- this indicating that at least one factor that alters *PRPF31* expression acts in *trans* \[[@R8]\]. One possible *trans*-acting factor was identified through the association of higher *PRPF31* expression and an expression quantitative trait locus (eQTL) at 14q21-23, although the exact factor was not characterized \[[@R3]\]. It was also shown that variable expression of *CNOT3* is an important factor in determining *PRFP31* expression level - with increased levels of CNOT3 protein causing transcriptional repression of *PRPF31* \[[@R9]\]. CNOT3 is a component of the Ccr4-Not transcription complex, which is a global regulator of RNA polymerase II-mediated transcription \[[@R10]\].

Attempts to generate mouse models of *PRPF31*-associated adRP have failed to yield animals with a retinal degeneration phenotype. Neither *Prpf31* knock-in animals nor knock-out animals displayed retinal degeneration, and the animals did not have any visual defect at up to 18 months of age \[[@R11]\]. There is some evidence that *Prpf31* knockout mice develop changes within the retinal pigment epithelium (RPE), with vacuolation, loss of the basal infoldings and accumulation of amorphous deposits between the RPE and Bruch's membrane \[[@R12]\]. There was not, however, death of retinal photoreceptor cells (the primary histological and pathological change in human disease) and no change in retinal function was reported -- and so these animals cannot be considered a model for human disease \[[@R12]\]. It is possible that the same RPE changes are observed in asymptomatic individuals, but this study is not feasible. It can be concluded that in mouse, 50% of protein level is sufficient for normal retinal function.

Regulation of gene expression is central to pathogenesis of *PRPF31* mutations in humans and also the failure of animal models of disease and it is necessary, therefore, to understand the 5′ architecture of the *PRPF31* gene. *PRPF31* and *TFPT* are arranged in a bidirectional gene pair, with partially shared exon 1, at chromosome 19q13.4. It is increasingly recognised that many genes exist in bidirectional pairs, which are defined as two genes that lie in a head-to-head arrangement, on opposite DNA strands, with less than 1kb separating their transcription start site (TSS).

*TFPT*, also known as *CF3 fusion partner* or *FB1*, encodes a 253 amino acid protein, that was first identified in some cases of paediatric pre-B-cell acute lymphoblastic leukaemia as the fusion partner of the transcription factor E2A \[[@R13]\]. A role for the human protein has not yet been described, but the rat homologue, *Tfpt*, has been shown to be pro-apoptotic and might modulate cerebral apoptosis \[[@R14]\].

As differential expression of *PRPF31* underlies phenotypic non-penetrance, a study was undertaken to characterize the core promoter element of the gene (and the bidirectional gene pair, *TFPT*), as it was considered important to understand the transcriptional regulation of the gene in the normal population \[[@R15]\]. The work by Rose et al. \[[@R15]\] repeated and extended a previous promoter characterization study by Brambillasca et al. \[[@R16]\], which had assayed fragments from the reverse strand in order to characterize a putative *TFPT* promoter element. Dual luciferase reporter assay was performed and a fragment termed BiP was defined as the core promoter of *PRPF31*, whereas the core promoter of *TFPT* was defined as a fragment termed P.31-Luc \[[@R15]\].

It was considered that studying the conservation and evolution of the *PRPF31* and *TFPT* core promoters in several mammalian species might shed light on the complex regulation of these genes and the failure of mouse models of *PRPF31*-adRP. The present study design was based on the results of the study on the human genes \[[@R15]\], through the identification of regions homologous to the active human DNA fragments. The homologous genomic regions were tested by dual-luciferase reporter assay in order to assess conservation of gene regulation. Where homology with the human region was found to be low, novel fragments were assayed.

Methods {#S3}
=======

Bioinformatic analysis {#S4}
----------------------

Evolutionary conservation of regions was analyzed using ECR browser in NCBI DCODE software suite using default software settings for each program \[[@R17]\].

PAZAR transcription factor work space was used to find TFBS for *PRPF31* and *TFPT* promoters in human and monkey and bidirectional promoters of dog and mouse \[[@R18]\]. Transfac, Jaspar and Oreganno vertebrate profiles were used to define TFBS in conserved promoter regions. For the experimentally-defined mouse promoter region, analysis with classical vertebrate profiles of TF did not identify any TFBS.

In order to find TFBS in mouse, universal protein binding microarray data was used. UNIPROBE database (and its standard TF binding algorithm) was used to find TFBS in experimentally-defined mouse promoter sequence, using strict criterion of enrichment score =0.49 \[[@R19]\].

Genomic DNA extraction {#S5}
----------------------

Genomic DNA was isolated from mammalian cell lines using Wizard SV Genomic DNA Purification System (Promega, UK) according to manufacturer's instructions. Monkey DNA was extracted from cos-7 cell line, dog from MDCK cell line and mouse from IMCD3 cell line. All cell lines were purchased from ADCC.

Fragment design and amplification {#S6}
---------------------------------

The genomic DNA sequence in the three test species was examined and fragments homologous to the three human fragments identified. In the mouse, where homology was limited, we initially looked for any conserved TFBS, but there were none observed. Therefore, fragments surrounding the *Prpf31* TSS were designed arbitrarily, according to possibility of PCR amplification in a difficult GC-rich region. In the dog, where the homologous region was approximately 2000bp upstream of *Prpf31* TSS, fragments were designed immediately adjacent to the TSS also. The twelve regions of interest were amplified by PCR using KOD polymerase (Novagen) and cloned into pGL3-basic vector (Promega, UK) in both forward (indicated by +) and reverse (indicated by −) strand orientation. Primers and PCR conditions can be seen in [Table 6](#T6){ref-type="table"}. In total, twelve regions were selected for assay by dual luciferase reporter assay ([Figure 2](#F2){ref-type="fig"}).

Dual luciferase reporter assays {#S7}
-------------------------------

The pGL3-reporter constructs were transfected into RPE-1 and HeLa cell lines. Additionally, due to concerns about species-specific transcription factor differences, mouse constructs were transfected into IMCD3 cell lines, and dog constructs into MDCK cell lines. Dual luciferase reporter assays were performed in quadruplicate, on three separate occasions. A negative control (pGL3-basic) and positive control (minimal thymidine kinase promoter, pTK) was assayed in each experiment. The transfection protocol and dual-luciferase reporter assay were performed as previously described \[[@R15]\]. Reporter assay data was analysed by firstly standardizing for cell number, by calculating the ratio of firefly luciferase (test) to renilla luciferase (control). This value was then compared to the pTK values, as pTK is considered a gold-standard basic promoter and, therefore, if a fragment has equivalent or greater activity, it can be considered an active regulatory region.

*Prpf31* expression studies {#S8}
---------------------------

Whole eye and retina tissues were obtained from DBA/2, 129S2/ Sv and C57Bl/6J adult wild-type mice, ten animals from each strain were used. The whole eye from the right side and the retina from the contralateral side were collected from each animal. Total RNA was extracted using TRIzol kit (Gibco BRL) according to the manufacturer's instructions. cDNA was prepared using the QuantiTect^®^ Reverse Transcription kit (Qiagen) and 1 μg of RNA as template for each reaction. Real-time PCR was carried out with the GeneAmp 7500 System (Applied Biosystem). The PCR reaction was performed using 1 μl cDNA, 12.5 ml SYBR Green Master Mix (Applied Biosystem) and 400 nM primer. Water was added to make a total reaction volume of 20 μl. The PCR conditions were as follows: preheating, 50°C for 2 min and 95°C for 10 min; cycling, 40 cycles of 95°C for 15 s and 60°C for 1 min. Quantification results were expressed in terms of the cycle threshold (Ct). The Ct values were averaged for each triplicate. Both the *Gapdh* (F- GTATGACTCCACTCACGGCAAA; R- TTCCCATTCTCGGCCTTG) and *Hprt* (F- GAAGAGCTACTGTAATGATCAG; R- GCTGTACTGCTTAACCAGGG) were used as endogenous controls (reference markers). Differences between the mean Ct values of Prpf31 (F- TCGTGTGGACAGCTTCCATG; R- TTCTTCCGCTGCCCATCAAG) and those of the reference genes were calculated as ΔCt=CT*~Prpf31~*−CT*~Hprt~* ~(or~ *~Gapdh~*~)~. Relative fold changes in expression levels were determined as 2−^ΔΔCt^, the *Prpf31* expression data was normalised with the DBA/2 mouse strain.

Results {#S9}
=======

Bioinformatic analysis {#S10}
----------------------

The core promoter of the human *PRPF31* gene had previously been identified as Bi-P, the region at chr19:54618440-54619393 (hg19) and the *TFPT* promoter was contained within this region (chr19:54618440-54619133, hg19) \[[@R15]\]. Conservation of the defined regulatory region was analyzed in several species from different lineages, showing a remarkably low level of conservation ([Figure 1](#F1){ref-type="fig"}). It was particularly evident that chicken, *Xenopus* and zebrafish shared no homology (defined as \<25%) with the human region. In the mammalian lineage, macaque and dog shared a high level of homology (defined as \>50%) with human, whereas mouse only had a low level homology over a very short distance, the majority of the defined human promoter having no homologous region in mouse. Interestingly, it was noted that although the base sequence was conserved between dog and human, the gene transcription start site (TSS) was different, meaning the homologous sequence in dog was located some 2000bp from the canine *Prpf31* TSS.

In light of these findings, three species were selected for study: *C. sabaeus, C. familiaris* and *M. musculus*. It was thought that these species would be interesting, as the green monkey had high homology to the human promoter, the dog had homology in sequence but different genome architecture and the mouse appeared to have different gene regulation entirely.

Definition of core promoter in *C. sabaeus* {#S11}
-------------------------------------------

Three fragments from the *C. sabaeus* (green monkey) genome that showed very high homology to the human active promoter elements were tested by dual-luciferase reporter assay ([Figures 2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}, [Table 1](#T1){ref-type="table"}).

The assay showed that P.31-Luc- had the strongest reporter activity in the reverse strand (*TFPT*) orientation \[2.29 ± 0.30 (HeLa); 1.85 ± 0.32 (RPE-1)\], this confirmed that P.31-Luc was a core promoter with moderate activity, controlling the expression of *TFPT* in monkey. The *TFPT* promoter was, therefore, conserved between monkey and human.

In the forward strand (*PRPF31*) orientation, both Bi-P+ and Δ2+ had strong promoter activity \[Bi-P+: 3.91 ± 0.52 (HeLa); 5.12 ± 0.95 (RPE-1); Δ2+: 3.74 ± 0.33 (HeLa); 5.72 ± 0.86 (RPE-1)\]. It was clear that both fragments were capable of acting as strong promoter elements. There was no significant difference between the two fragments and, therefore, it was not possible to state unequivocally which was the active core promoter element *in vivo*. It is likely, however, that Bi-P is the promoter fragment, as Δ2 does not contain the gene TSS, and would not, therefore, allow correct binding of RNA polymerase II. The Bi-P+ and Δ2+ fragments both showed strong promoter activity in human and, as such, the function of these two fragments was conserved between human and green monkey.

Definition of core promoter in *C. familiaris* {#S12}
----------------------------------------------

Initially, two fragments immediately upstream to the dog *PRPF31* TSS were designed and assayed, these fragments being homologous to intron 1 of the human gene (termed Σ1 and Σ2). Luciferase assay in HeLa, RPE-1 and MDCK cell lines showed that these fragments possessed no luciferase activity ([Figures 2](#F2){ref-type="fig"} and [4A](#F4){ref-type="fig"}, [Table 2](#T2){ref-type="table"}).

Subsequently, the fragments that showed homology to the human active promoter fragments -- but located 2000bp from *Prpf31* TSS -- were tested by dual luciferase reporter assay in RPE-1, HeLa and MDCK cell lines ([Figures 2](#F2){ref-type="fig"} and [4B--D](#F4){ref-type="fig"}, [Table 2](#T2){ref-type="table"}). This showed that the P.31-Luc - fragment was also the core *Tfpt* promoter in dog, indeed acting as a stronger promoter than that seen in human \[6.16 ± 0.74 (HeLa); 2.40 ± 0.41 (RPE-1); 4.98 ± 0.97 (MDCK)\]. The fragment homologous to the human *PRPF31* promoter, Bi-P+, did not have strong promoter activity in dog, with reporter activity less than, or very similar to, pTK \[0.48 ± 0.09 (HeLa); 0.91 ± 0.13 (RPE-1); 1.16 ± 0.14 (MDCK)\]. This suggests that the Bi-P+ fragment does not control the expression of *Prpf31* in the dog.

It was apparent, however, that the constituent elements of Bi-P+ (P.31-Luc + and Δ2+) had promoter activity, although this was variable between the cell lines tested. In both HeLa and RPE-1 cell lines, Δ2+ had the highest promoter activity \[4.71 ± 0.67 (HeLa); 2.58 ± 0.58 (RPE-1)\], whereas P.31-Luc+ showed only slight activity \[1.77 ± 0.42 (HeLa); 0.99 ± 0.30 (RPE-1)\]. This situation was not observed in MDCK cell line, where P.31-Luc+ possessed strong promoter activity \[5.01 ± 0.52 (MDCK)\], although Δ2+ also displayed good reporter activity \[2.65±0.46 (MDCK)\]. This suggested that the strong activation of P.31-Luc+ requires the binding of a dog-species specific transcription factor (TF), and that P.31-Luc is a true bi-directional promoter in *C. familiaris*, controlling the expression of both *Prpf31* and *Tfpt*.

Definition of core promoter in *M. musculus* {#S13}
--------------------------------------------

There was very little homology between the regions surrounding *Prpf31* TSS in the mouse genome and the corresponding region in the human genome. Of the three active human fragments (Bi-P, P.31-Luc and Δ2), only Δ2 had a homologous region in the murine genome (approximately 60% conservation). Therefore, the Δ2 fragment and four additional fragments that shared no homology with human regions (termed ψ1--4) were assayed by dual-luciferase reporter assay in both forward- and reverse-strand orientations ([Figures 2](#F2){ref-type="fig"} and [5](#F5){ref-type="fig"}, [Table 3](#T3){ref-type="table"}).

In mouse, ψ1 acted as a true bidirectional promoter, controlling the expression of *Tfpt* and *Prpf31*. The results were most clear in IMCD3 (murine) cell line, where ψ1 had very strong reporter activity in the forward strand orientation (6.61 ± 0.72) and the reverse strand orientation (13.02 ± 0.75). The same effect was observed in HeLa cell line (forward strand: 4.50 ± 0.60; reverse strand: 6.25 ± 0.62). In RPE-1 cell line, ψ1 had the strongest activity in the forward strand orientation (2.85 ± 0.35); in the reverse strand orientation the situation was more complex, as three fragments had relatively strong reporter activity \[Δ2: (3.22 ± 0.26), ψ1: (3.76 ± 0.75), ψ2: (4.10 ± 0.22)\]. This result might be due to the different transcription factor profile in RPE-1 cells, and the differences between human and murine transcription factors. Given the clear result in IMCD3 cell line (the most realistic model of the *in vivo* situation), it was concluded that ψ1 acted as a bidirectional promoter controlling the expression of both *Tfpt* and *Prpf31*.

The ψ1 region in mouse shared no significant homology with any human chromosomal region, with only very short regions (\<54bp) of imperfect alignment with human chromosomes 8, 14, 19, 20 and X ([Table 4](#T4){ref-type="table"}).

Prediction of transcription factor binding sites {#S14}
------------------------------------------------

A bioinformatic approach was taken to identify putative classical TF binding sites (TFBS) within the experimentally-defined promoters in monkey, dog and mouse. The transcription factor workspace of PAZAR was used to look for TFBS in the characterized promoters that showed conservation with human defined promoter. For mouse prediction of TFBS by pairwise conservation between mouse and dog was attempted.

As expected, there was a general overlap of TFBS between human and monkey, for both *PRPF31* and *TFPT* promoters (enriched in signal transduction mechanism and transcription functions) ([Figure 6A](#F6){ref-type="fig"}). Moreover, it was observed that three TFBS (*Myf, Gata1* and *SP1*) were shared between human, monkey and dog ([Figure 6A and 6B](#F6){ref-type="fig"}). It was not possible, however, to identify any putative classical TFBS in the mouse promoter using pairwise conservation between mouse and human or mouse and dog (scanning for standard vertebrate transcription factor profiles of Jaspar, Transfac & Oreganno). It was also observed that the human promoter region was enriched with strong H3K4Me3 mark for 7 ENCODE cell lines assayed for this histone methylation ([Figure 6](#F6){ref-type="fig"}).

As a conservation based approach could not be used in mouse, due to lack of homology between mouse and human sequence, an analysis was performed using universal protein binding microarray (PBM) data, to identify putative TFBS in the experimentally-defined murine bidirectional promoter (ψ1). A strict threshold of 0.49 TF enrichment was used and all mouse PBM experiments in UNIPROBE database were searched. A range of TF having strong binding affinity to oligonucleotides of mouse promoter sequence were defined ([Figure 7](#F7){ref-type="fig"}, [Table 5](#T5){ref-type="table"}). Amongst these, some TF classes were computationally predicted to bind to characterized promoter in monkey and dog (e.g. *TCFE2A*, zinc finger family, *NR2F*). However, analysis of functional enrichment showed that TFs binding to the mouse promoters were enriched in purine metabolism and also *Hox* cluster genes (which are important during development and homeostasis). These findings support the divergent evolution of promoter sequences of human and mouse, by gain of a new function in the mouse lineage.

Study of *Prpf31* expression in *M. musculus* {#S15}
---------------------------------------------

In human populations, *PRPF31* displays differentially expressed wild-type alleles, with highly expressed alleles providing protection against the clinical manifestation of *PRPF31*-associated adRP. We sought to analyze whether there was variable expression of *Prpf31* in *M. musculus*. Real time qPCR experiments were performed, to quantify *Prpf31* expression levels in mouse eyes and retinas. In order to avoid interference due to the genetic background or the age, animals belonging to three different wildtype mouse strains (DBA/2, 129S2/Sv and C57Bl/6J) and of the same age (8 weeks old) were analyzed. To reach a statistical significant number of tested individuals, thirty mice (ten mice for each strain) were analyzed. *Prpf31* expression level was tested in the eye and the contralateral retina of each mouse. Experiments were performed using *Hprt* and *Gapdh* genes as endogenous control. There was no statistically significant difference in *Prpf31* expression levels between the three mouse strains, either comparing eye or retinal cDNAs ([Figure 8](#F8){ref-type="fig"}). Overall, our data suggest that in the mouse population there is no differential expression of *Prpf31* alleles.

Discussion {#S16}
==========

The aim of this investigation was to identify and characterize the core promoters controlling the expression of *PRPF31* and *TFPT* in three species, green monkey (*C. sabaeus*), domestic dog (*C. familiaris*) and house mouse (*M. musculus*).

In green monkey, the core promoter of *TFPT* was defined as a fragment (P.31-Luc) spanning −354 to +355 relative to the *TFPT* TSS, with comparatively weak promoter activity. It was more difficult to define the *PRPF31* promoter in monkey, as both Bi-P+ and Δ2+ had strong, and very similar, promoter activity. It was, however, considered unlikely that Δ2 fragment is the true core promoter element of *PRPF31*, as it does not flank the TSS. It is apparent, however, that this fragment is capable of acting as a promoter *in vitro* and is likely, therefore, to harbour a RNA polymerase II binding site and other TFBS. As Bi-P spans the *PRPF31* TSS (−406 to +584), it is more likely that Bi-P is the *in vivo* promoter, as this would allow correct binding of the RNA polymerase II. The two defined core promoters, P.31-Luc and Bi-P, are homologous to the experimentally-defined human promoters \[[@R15]\]. Furthermore, there were a large number of evolutionarily conserved TFBS between human and monkey species. This was to be expected, as the green monkey fragments share \>90% homology and there has, therefore, been conservation of the active promoter elements.

In dog, P.31-Luc was defined as a true bidirectional promoter, controlling the expression of both *Prpf31* and *Tfpt*. P.31-Luc spanned −510bp to +208bp relative to the *Tfpt* TSS in the dog genome, and had strong promoter activity in this orientation in the three tested cell lines. The fragment shared 73% homology with the human *TFPT* promoter, so both the sequence and the function of this region were conserved between the domestic dog and humans.

The region immediately upstream to canine *Prpf31* TSS had no reporter activity; but, rather, a long-range promoter was shown to control the expression of *Prpf31* in dog. P.31-Luc was defined as the canine core promoter, and spanned −2580 to −1857 relative to the *Prpf31* TSS (genomic co-ordinates chr1:103068699-103069421, canFam3). Long-range promoter elements bind RNA polymerase II at the TSS (in the same manner as canonical promoters), but distally bound TFs are later brought into close apposition to the gene TSS by DNA looping, this allowing activation of the RNA polymerase II complex. It is unclear why the sequence that is homologous to the primate exon 1 is not transcribed in the canine lineage.

Interestingly, the Bi-P fragment, which shared 68% homology with the human *PRPF31* core promoter did not show reporter activity. The difference between humans and dog indicates that the functional TFBS in Bi-P have been lost in dog, or that new functional sites have evolved since the divergence of the primate and canine lineages; the latter is more likely, as functional domains tend to have a positive selection pressure and are, therefore, rarely lost through evolution. Analysis of TFBS identified three binding sites that were conserved between human, monkey and dog, all of which are located within the human/ canine P.31-Luc portion, which correlates with the experimental findings.

Furthermore, it should be noted that the human CNOT3 binding site was not conserved in either monkey or dog, despite the higher level of homology between the three species. It remains to be seen whether this is reflected in less variable *PRPF31* expression levels in wild populations of these species, given that variable *CNOT3* expression was described as an important modulator of *PRPF31* expression in the human genome \[[@R19]\]. Another interesting finding of the TFBS prediction was the finding of a conserved NR2E3 binding site between human and monkey. NR2E3 is a transcription factor that plays an important role in developmental differentiation of the photoreceptors and, after development, is specifically expressed in post-mitotic photoreceptors \[[@R20]\]. As such, regulation of *PRPF31* by this factor might be part of the explanation of the retina-specific phenotype of *PRPF31* mutations.

A mouse fragment, ψ1 (chr7:3629316-3630581, mm10), was defined as a bidirectional promoter controlling the expression of both *Tfpt* and *Prpf31*. It was notable that the murine *Prpf31* 5′ region shared little homology with the human *Prpf31* 5′ region; indeed, the region that controlled expression of *Prpf31* in mouse has no homologous region in man. Bioinformatic analysis of conserved TFBS demonstrated that the mouse promoter was not regulated by any shared putative TFs with either human or dog. Instead, the mouse bidirectional promoter was enriched with TFBS for *Hox* family TFs and purine metabolism TFs, indicating significant divergent evolution in the mouse lineage.

It is necessary to speculate on the bidirectional gene architecture of the *PRPF31-TFPT* gene pair, which is conserved throughout the mammalian lineage, as well as in other vertebrate species, such as chicken, *Xenopus*, anole lizard, *Pelodiscus* turtle and even the coelacanth. The phenomenon of bidirectional gene pairs has been observed across most genomes, including yeast, nematode, fish and mammalian and it has been estimated that up to 10% of human genes exist in this divergent arrangement \[[@R21]\]. Bidirectional genes are controlled by a bidirectional promoter and this might allow co-transcription of the two genes, in a way similar to the prokaryotic operon. Bidirectional promoters are characterized by CpG islands, that overlap the exon 1 of both genes and this strongly suggests that the level of gene expression in bidirectional gene pairs is controlled by CpG methylation \[[@R21],[@R22]\]. It is unclear why the bidirectional *TFPT-PRPF31* gene pair has arisen, given that the two genes share neither protein function nor temporal expression. *PRPF31* is a ubiquitously expressed spliceosome component, whilst *TFPT* is involved in p53-independent cellular apoptosis and is thus mainly active under conditions of cellular stress. It is difficult to imagine a shared selection pressure that might have influenced the gene architecture of these two very different genes. It should be noted, however, that during cellular stress the splicing machinery genes are down-regulated and, as such, the bidirectional gene architecture might bear relevance to the complex changes in gene expression that occur in situations of cellular stress \[[@R23]\].

In this work, it was also demonstrated that there is not variable expression of *Prpf31* in a population of mice from three different strains. This suggests that the differential expression of *Prpf31* has arisen after the evolutionary divergence of rodent and primate lineages. It could be inferred that the different 5′ architecture of the two genes is responsible for the lack of differential expression in the mouse. It has been demonstrated that one major factor that determines human *PRPF31* expression level is repression of transcription by binding of CNOT3 to the *PRPF31* core promoter \[[@R9]\]. As the CNOT3 binding site is not conserved between mouse and human, it follows that differential gene expression is not observed in mouse populations. The different gene regulation is a plausible explanation of why mouse models of human *Prpf31* mutations have failed to yield a disease phenotype \[[@R11],[@R12]\]. Furthermore, other *cis-*acting factors within the *PRPF31* 5′ region that are present in human, but not in mouse, might contribute to the observed phenotypic differences.

It appears then, that in evolutionary terms, the high-expressing allele is older and, since the divergence of rodents and primate lineages, a lower-expressing allele has evolved. This raises complex evolutionary questions that will need to be addressed through systematic bioinformatic analysis of phylogenetic and genomic sequencing data. These analyses might lead to a deeper understanding of this unusual situation, whereby there appears to be rapidly-evolving control of an evolutionarily-conserved gene, with different regulatory mechanisms in relatively closely related species.
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**PAZAR** <http://www.pazar.info/>

**UNIPROBE** <http://the_brain.bwh.harvard.edu/uniprobe/>

![Evolutionary conservation of the Bi-P region, defined as the core promoter for *PRPF31* in the human genome. The genome architecture of PRPF31 and TFPT is illustrated, showing exon 1 and TSS of each gene. Degree of conservation is indicated by vertical height of peaks, with areas of significant evolutionary conservation highlighted by a dotted black line. Yellow -- non-coding exons, blue - coding exons, salmon pink - introns, green -- transposable elements and repeats.](nihms627091f1){#F1}

![Schematic representation of the genomic regions assayed by dual-luciferase reporter assay. The three fragments with defined reporter activity in human are illustrated, as well as the homologous regions in African green monkey, dog and mouse. The *PRPF31* TSS is indicated with a solid arrow, the *TFPT* TSS with a dashed arrow. Where appropriate, the percentage homology with the human fragment is indicated.](nihms627091f2){#F2}

![Results of dual-luciferase reporter assay using genomic sequence from *C. sabaeus* (green monkey) in HeLa cell line (A) and RPE- cell line (B). The data is presented as the average ratio of pGL3-insert to pTK, together with an error bar of ± one standard deviation, + refers to fragments tested in forward strand (*PRPF31*) orientation, − to reverse strand (*TFPT*) orientation. The absolute data values can be seen in [Table 1](#T1){ref-type="table"}.](nihms627091f3){#F3}

![Results of dual-luciferase reporter assay using genomic sequence from *C. familiaris* (domestic dog). The region immediately upstream to the gene transcription start site were initially assayed (A), followed by regions located 2000bp upstream \[(B)-Hela, (C) -- RPE-1, (D) -- MDCK\]. The data is presented as the average ratio of pGL3-insert to pTK, together with an error bar of ± one standard deviation, + refers to fragments tested in forward strand (*PRPF31*) orientation, − to reverse strand (*TFPT*) orientation. The absolute data values can be seen in [Table 2](#T2){ref-type="table"}.](nihms627091f4){#F4}

![Results of dual-luciferase reporter assay using genomic sequence from *M. musculus* (house mouse) in HeLa cells (A), RPE- cells (B) and IMCD3 cells (C). The data is presented as the average ratio of pGL3-insert to pTK, together with an error bar of ± one standard deviation, + refers to fragments tested in forward strand (*PRPF31*) orientation, − to reverse strand (*TFPT*) orientation. The absolute data values can be seen in [Table 3](#T3){ref-type="table"}.](nihms627091f5){#F5}

![Evolutionary conserved transcription factor binding sites (TFBS) in the experimentally-defined promoters of *PRPF31* and *TFPT* in monkey (A) and dog (B). TFBS conserved between all three species (human, monkey and dog) are underlined in red on (A). ORCA conserved regions highlight areas with high level of evolutionary conservation between human and the test species. The ENCODE derived H3K4Me3 marks indicate areas that are often found in, or near, promoters.](nihms627091f6){#F6}

![Transcription factor binding sites in the experimentally defined mouse bidirectional promoter (ψ1, located at murine chromosome 7:3629316-3630581, mm10), that were derived using protein binding microarray data, and oligonucleotide motifs of some representative transcription factors.](nihms627091f7){#F7}

![Expression of *Prpf31* in whole eye (black bars) and retina (grey bars) of three mouse strains. Data are normalized with the DBA/2 mouse strain. Error bars represent one standard error.](nihms627091f8){#F8}

###### 

Mean dual luciferase reporter assay ratio values and standard deviation (SD) using sequence from green monkey, assayed in HeLa and RPE-1 cell lines.

               HeLa    RPE-1   HeLa (SD)   RPE-1 (SD)
  ------------ ------- ------- ----------- ------------
  pTK          1.001   1.001   0.064       0.144
  pGL3-empty   0.008   0.082   0.004       0.018
  P.31-Luc −   2.289   1.852   0.299       0.323
  P.31-Luc +   0.966   1.012   0.176       0.202
  Δ2 −         1.997   0.926   0.429       0.342
  Δ2 +         3.744   5.716   0.326       0.864
  Bi-P −       0.322   1.168   0.089       0.432
  Bi-P +       3.907   5.118   0.522       0.947

###### 

Mean dual luciferase reporter assay ratio values and standard deviation (SD) using sequence from dog, assayed in HeLa, RPE-1 and MDCK cell lines.

               HeLa    RPE-1   MDCK    HeLa (SD)   RPE-1 (SD)   MDCK (SD)
  ------------ ------- ------- ------- ----------- ------------ -----------
  pTK          1.001   1.001   1.001   0.064       0.144        0.084
  pGL3-empty   0.008   0.082   0.083   0.004       0.018        0.015
  Σ2 −         0.080   0.084   0.058   0.023       0.027        0.025
  Σ2 +         0.062   0.058   0.043   0.025       0.015        0.012
  Σ1 −         0.053   0.031   0.044   0.020       0.010        0.016
  Σ1 +         0.090   0.181   0.038   0.030       0.052        0.018
  P.31-Luc −   6.164   2.399   4.979   0.743       0.414        0.967
  Δ2 −         4.499   1.357   3.384   0.968       0.209        0.786
  Bi-P −       0.398   0.704   0.787   0.036       0.119        0.207
  P.31-Luc +   1.766   0.995   5.011   0.419       0.299        0.528
  Δ2 +         4.712   2.579   2.653   0.666       0.576        0.461
  Bi-P +       0.485   0.910   1.168   0.092       0.129        0.143

###### 

Mean dual luciferase reporter assay ratio values and standard deviation (SD) using sequence from mouse, assayed in HeLa, RPE-1 and IMCD3 cell lines.

               HeLa    RPE-1   IMCD3    HeLa (SD)   RPE-1 (SD)   IMCD3 (SD)
  ------------ ------- ------- -------- ----------- ------------ ------------
  pTK          1.001   1.001   1.000    0.064       0.144        0.110
  pGL3-empty   0.008   0.082   0.055    0.004       0.018        0.010
  Δ2 −         1.910   3.219   1.822    0.258       0.447        0.192
  ψ4 −         0.403   0.523   0.396    0.147       0.134        0.098
  ψ3 −         0.659   0.318   2.059    0.185       0.042        0.202
  ψ2 −         3.296   4.095   2.283    0.222       0.570        0.276
  ψ1 −         6.253   3.758   13.023   0.624       0.753        1.356
  Δ2 +         0.875   0.372   0.395    0.161       0.136        0.065
  ψ4 +         0.430   1.512   0.384    0.096       0.294        0.134
  ψ3 +         1.960   1.352   1.912    0.355       0.202        0.160
  ψ2 +         0.449   0.451   0.642    0.083       0.152        0.127
  ψ1 +         4.495   2.849   6.609    0.596       0.347        0.719

###### 

Regions in the human genome that are homologous to the experimentally defined mouse promoter, demonstrating minimal homology.

  Accession        Chromosome   Max score   Total score   Query coverage   E value   Max identity
  ---------------- ------------ ----------- ------------- ---------------- --------- --------------
  NW_003571061.1   19           42.8        42.8          4%               1         78%
  NW_003571060.1   19           42.8        42.8          4%               1         78%
  NW_003571059.1   19           42.8        42.8          4%               1         78%
  NW_003571058.1   19           42.8        42.8          4%               1         78%
  NW_003571057.1   19           42.8        42.8          4%               1         78%
  NW_003571056.1   19           42.8        42.8          4%               1         78%
  NW_003571055.1   19           42.8        42.8          4%               1         78%
  NW_003571054.1   19           42.8        42.8          4%               1         78%
  NT_011109.16     19           42.8        42.8          4%               1         78%
  NW_001838498.2   19           42.8        42.8          4%               1         78%
  NT_011651.17     X            41          41            3%               3.5       81%
  NW_001842380.1   X            41          41            3%               3.5       81%
  NT_011362.10     20           41          41            2%               3.5       84%
  NW_001838666.1   20           41          41            2%               3.5       84%
  NT_026437.12     14           46.4        46.4          2%               0.082     91%
  NW_001838111.1   14           46.4        46.4          2%               0.082     91%
  NT_167187.1      8            41          41            1%               3.5       96%
  NW_001839128.2   8            41          41            1%               3.5       96%

###### 

Transcription factor binding sites identified within the murine promoter, found using mouse PBM experiments in UNIPROBE database.

  Gene Match   K-mer      Reverse Complement   Position   Enrichment Score
  ------------ ---------- -------------------- ---------- ------------------
  Zfp410       ACATCCCA   TGGGATGT             12         0.492169
  Nr2f2        TTGACCCT   AGGGTCAA             63         0.491182
  Zfp691       AGGAGCAC   GTGCTCCT             90         0.494015
  Zfp691       GGAGCACC   GGTGCTCC             91         0.491563
  Tcfe2a       ACCACCTG   CAGGTGGT             228        0.492541
  Max          CCCACGTG   CACGTGGG             348        0.494126
  Bhlhb2       CCACGTGC   GCACGTGG             349        0.493300
  Max          CCACGTGC   GCACGTGG             349        0.497488
  Bhlhb2       CACGTGCC   GGCACGTG             350        0.498400
  Max          CACGTGCC   GGCACGTG             350        0.492097
  Osr1         CCAGTAGC   GCTACTGG             479        0.491743
  Osr2         CCAGTAGC   GCTACTGG             479        0.495304
  Osr1         CAGTAGCT   AGCTACTG             480        0.491785
  Osr2         CAGTAGCT   AGCTACTG             480        0.494346
  Gabpa        GCTTCCGG   CCGGAAGC             490        0.494322
  Gabpa        CTTCCGGC   GCCGGAAG             491        0.493443
  Lef1         TCTTTGAT   ATCAAAGA             582        0.493387
  Tcf7l2       TCTTTGAT   ATCAAAGA             582        0.493092
  Tcf7         CTTTGATG   CATCAAAG             583        0.492072
  Tcf3         CTTTGATG   CATCAAAG             583        0.493912
  Lef1         CTTTGATG   CATCAAAG             583        0.496125
  Tcf7l2       CTTTGATG   CATCAAAG             583        0.496806
  Jundm2       TGATGACG   CGTCATCA             586        0.493965
  Jundm2       GATGACGT   ACGTCATC             587        0.495828
  Gm5454       GCTTCCGG   CCGGAAGC             490        0.495590
  Etv1         GCTTCCGG   CCGGAAGC             490        0.495020
  Elk3         GCTTCCGG   CCGGAAGC             490        0.495800
  Etv6         GCTTCCGG   CCGGAAGC             490        0.492150
  Etv4         GCTTCCGG   CCGGAAGC             490        0.491930
  Fli1         GCTTCCGG   CCGGAAGC             490        0.492160
  Elk4         GCTTCCGG   CCGGAAGC             490        0.491940
  Ets1         GCTTCCGG   CCGGAAGC             490        0.491280
  Elf4         GCTTCCGG   CCGGAAGC             490        0.493140
  Etv5         GCTTCCGG   CCGGAAGC             490        0.495350
  Erg          GCTTCCGG   CCGGAAGC             490        0.493290
  Elk1         GCTTCCGG   CCGGAAGC             490        0.494580
  Gabpa        GCTTCCGG   CCGGAAGC             490        0.492650
  Elf2         GCTTCCGG   CCGGAAGC             490        0.492000
  Gm5454       CTTCCGGC   GCCGGAAG             491        0.492270
  Etv1         CTTCCGGC   GCCGGAAG             491        0.491880
  Elk3         CTTCCGGC   GCCGGAAG             491        0.494370
  Fli1         CTTCCGGC   GCCGGAAG             491        0.490020
  Etv5         CTTCCGGC   GCCGGAAG             491        0.493190
  Elk1         CTTCCGGC   GCCGGAAG             491        0.491590
  Gabpa        CTTCCGGC   GCCGGAAG             491        0.490780
  Cphx         TTTGATTG   CAATCAAA             620        0.491680
  Lhx8         TTGATTGG   CCAATCAA             621        0.491150
  Cphx         TTGATTGG   CCAATCAA             621        0.496010
  Duxl         TTGATTGG   CCAATCAA             621        0.496350
  Cphx         TGATTGGC   GCCAATCA             622        0.491310
  Hoxd12       GTTTACGA   TCGTAAAC             631        0.493010
  Hoxa13       GTTTACGA   TCGTAAAC             631        0.492860
  Hoxd11       TTTACGAC   GTCGTAAA             632        0.497210
  Hoxc12       TTTACGAC   GTCGTAAA             632        0.497690
  Hoxc13       TTTACGAC   GTCGTAAA             632        0.490000
  Hoxd12       TTTACGAC   GTCGTAAA             632        0.498500
  Hoxb9        TTTACGAC   GTCGTAAA             632        0.494760
  Hoxc11       TTTACGAC   GTCGTAAA             632        0.498230
  Hoxc10       TTTACGAC   GTCGTAAA             632        0.497220
  Hoxa11       TTTACGAC   GTCGTAAA             632        0.497390
  Hoxc13       TTTATTAG   CTAATAAA             666        0.492680
  Hoxa13       TTTATTAG   CTAATAAA             666        0.493680
  Gabpa        ATTTCCGG   CCGGAAAT             640        0.495780
  Ehf          ATTTCCGG   CCGGAAAT             640        0.490102
  Zbtb12       GGGTTCTA   TAGAACCC             707        0.492551
  Zbtb12       GGTTCTAG   CTAGAACC             708        0.498015
  Zbtb12       GTTCTAGG   CCTAGAAC             709        0.497873
  Gm4881       CATTTCCG   CGGAAATG             639        0.490280
  Erg          CATTTCCG   CGGAAATG             639        0.490560
  Gm4881       ATTTCCGG   CCGGAAAT             640        0.495580
  Gm5454       ATTTCCGG   CCGGAAAT             640        0.495450
  Etv3         ATTTCCGG   CCGGAAAT             640        0.490630
  Etv1         ATTTCCGG   CCGGAAAT             640        0.494530
  Elk3         ATTTCCGG   CCGGAAAT             640        0.493980
  Etv6         ATTTCCGG   CCGGAAAT             640        0.496360
  Etv4         ATTTCCGG   CCGGAAAT             640        0.493710
  Fli1         ATTTCCGG   CCGGAAAT             640        0.497170
  Elk4         ATTTCCGG   CCGGAAAT             640        0.495700
  Ets1         ATTTCCGG   CCGGAAAT             640        0.496500
  Elf4         ATTTCCGG   CCGGAAAT             640        0.495400
  Etv5         ATTTCCGG   CCGGAAAT             640        0.494770
  Erg          ATTTCCGG   CCGGAAAT             640        0.496890
  Elk1         ATTTCCGG   CCGGAAAT             640        0.493770
  Elf5         ATTTCCGG   CCGGAAAT             640        0.492260
  Gabpa        ATTTCCGG   CCGGAAAT             640        0.496960
  Elf3         ATTTCCGG   CCGGAAAT             640        0.493910
  Elf2         ATTTCCGG   CCGGAAAT             640        0.495170
  Ehf          ATTTCCGG   CCGGAAAT             640        0.493370
  Zfp691       TAGTGCTC   GAGCACTA             1085       0.495547
  Zfp691       AGTGCTCT   AGAGCACT             1086       0.493492

###### 

Primer sequence and PCR conditions used for production of genomic fragments.

  Species      Fragment   F                           R                           Annealing Temp   Extension Time
  ------------ ---------- --------------------------- --------------------------- ---------------- ----------------
  **Monkey**   Δ2         GGAGAATCGTTTGAACCCTGGAGAC   CCACAGCAATTCTCCGCTTAGCAG    63               10, 30
               P.31-Luc   GATGACGTCTCATGCTCGCGCC      GCAGTCCAAACCCCTAGCCT        63               14, 43
               Bi-P       GGAGAATCGTTTGAACCCTGGAGAC   GCAGTCCAAACCCCTAGCCT        63               20, 60
  **Dog**      Σ1         CTCTACAGCCCACTCACCATCTTG    GCTCTTTTCCACATCATGGGAC      63               27, 82
               Σ2         CTCTACAGCCCACTCACCATCTTG    CCTAGTTCTGGGAGGTTTGTTC      63               14, 43
               Δ2         GCTCTAGCGACCTAAACCCGTCTC    CTAGGGCGATGCTCCGCTTAGCA     63               11, 33
               P.31-Luc   CCCACTGATGACGTCCCAGGC       GAACTCCAACTCCTAGCTTTTTTCC   63               14, 43
               Bi-P       GCTCTAGCGACCTAAACCCGTCTC    GAACTCCAACTCCTAGCTTTTTTCC   63               20, 60
  **Mouse**    Δ2         CTTTGCCTAACCCGGCTCTT        CCAAAGCGAATCTCTGTTTAGC      60               10, 30
               ψ1         CATCAGCCAGAGACATCCCAAG      CAGACCCTAGCCTCCTCCCTC       60               25, 75
               ψ2         CATCAGCCAGAGACATCCCAAG      CCAAAGCGAATCTCTGTTTAGC      57               16, 48
               ψ3         CTTTGCCTAACCCGGCTCTT        CAGACCCTAGCCTCCTCCCTC       57               20, 60
               ψ4         GGCTCTCTTTGATGACGTTTAC      CAGACCCTAGCCTCCTCCCTC       57               14, 40
